


RECEIVED

AUG 18 2003

TECH CENTER 1600/2900



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.  
ELI LILLY AND COMPANY

By [Signature]

Date 8-11-03

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Charles Jack Fisher et al. )  
Serial No. : 09/998,393 )  
Filed : November 2, 2001 ) Group Art Unit:  
For : METHODS FOR TREATING SEPSIS ) 1654  
Docket No. : X-12444A ) Examiner:  
J. RUSSEL

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Identification of Person Making This Disclaimer

I, Thomas E. LaGrandeur, am employed by Eli Lilly and Company, and I am an agent of record in the above-identified patent application. In that capacity, I am authorized to sign this disclaimer on behalf of Eli Lilly and Company.

Identity of Assignee

I hereby verify that the assignee owning all of the interest in this application is:

Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, Indiana 46285

08/15/2003 MMKONEN 00000095 050840 09998393

01 FC:1814

110.00 DA

**Recordal of Assignment in PTO**

The assignment was recorded on October 15, 1999,  
Reel 010303, Frame 0955.

**Extent of Interest**

The extent of Eli Lilly and Company's interest is  
in the whole of this invention.

**Disclaimer**

I hereby disclaim the terminal part of any patent  
granted on this application, which would extend beyond the  
expiration date of:

United States Patent No. 6,156,734 and hereby  
agree that any patent granted on this application shall be  
enforceable only for and during such period that the legal  
title to the patent shall be the same as the legal title to  
United States Patent No. 6,156,734.

I do not disclaim any terminal part of any patent  
granted on this application prior to the expiration date of  
the full statutory term of United States Patent No.  
6,156,734 in the event that it later: expires for failure  
to pay a maintenance fee, is held unenforceable, is found  
invalid, is statutorily disclaimed in whole or terminally  
disclaimed under 37 C.F.R. 1.321, has all claims cancelled  
by a reexamination certificate, or is otherwise terminated  
prior to expiration of its full statutory term other than as  
presently shortened by any terminal disclaimer.


**Fee Payment**

Please charge \$110.00, the fee set forth in  
37 C.F.R. 1.20(d), and charge any additional fees which may  
be required by this or any other related paper, or credit

any overpayment to Deposit Account No. 05-0840, in the name of Eli Lilly and Company. Two copies of this disclaimer are enclosed.

ELI LILLY AND COMPANY

By:

  
Thomas E. LaGrandeur  
Agent for Applicants  
Registration No. 51,026  
Phone: 317-651-1527

Eli Lilly and Company  
Patent Division/TEL  
Lilly Corporate Center  
Indianapolis, Indiana 46285

August 11, 2003